Literature DB >> 1666460

Biologic tolerance of two different low molecular weight heparins.

H M Christiansen1, M R Lassen, L C Borris, J V Sørensen, H B Rahr, L N Jørgensen, P W Jørgensen, O Hauch.   

Abstract

Heparin preparations have been used for prophylaxis and treatment of deep vein thrombosis for many years. Several biologic effects of heparin are known. Since 1978, there have been several reports about reversible elevation in serum values of AST and ALT in patients and healthy volunteers given heparin in small and high doses. Few studies report similar events in patients given LMW heparins. Results of two randomized studies (A and B) comprising 456 patients undergoing THR are presented. Two different compounds of LMW heparin (Logiparin or Enoxaparin) were used for thromboprophylaxis. Significant elevation during the postoperative period of AST and AP in study A, and AST, ALT, AP, LDH, and CK in study B were demonstrated in patients given LMW heparins in both studies. In study A the percentages of patients with normal preoperative values who reached pathologic values were 35% for AST and 15% for AP. In study B the percentages of patients with normal preoperative values who reached pathologic values were 36% for AST, 17% of ALT, 14% for AP, and 36% for LDH. The possible biologic mechanisms and the clinical perspectives are discussed. In all cases the changes in the liver enzymes returned to preoperative levels within 14 days.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1666460     DOI: 10.1055/s-2007-1002654

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  6 in total

1.  Effects of Bivalirudin and Unfractionated Heparin on Liver and Renal Function in Chinese Patients with Coronary Artery Disease Undergoing Coronary Angiography with/without Percutaneous Coronary Intervention.

Authors:  Qiaowei Jia; Jia Hu; Wenfeng Ji; Liansheng Wang; Enzhi Jia
Journal:  J Clin Transl Hepatol       Date:  2021-04-09

Review 2.  Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease.

Authors:  Susan M Cheer; Christopher J Dunn; Rachel Foster
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 3.  Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease.

Authors:  S Noble; D H Peters; K L Goa
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546

Review 4.  Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders.

Authors:  H A Friedel; J A Balfour
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

5.  The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers.

Authors:  A H Harrill; J Roach; I Fier; J S Eaddy; C L Kurtz; D J Antoine; D M Spencer; T K Kishimoto; D S Pisetsky; B K Park; P B Watkins
Journal:  Clin Pharmacol Ther       Date:  2012-06-27       Impact factor: 6.875

6.  EVALUATION OF HEPATIC FUNCTION AMONG PATIENTS UNDERGOING TOTAL HIP ARTHROPLASTY USING ENOXAPARIN.

Authors:  Felipe Vitiello Wink; Carlos Roberto Schwartsmann
Journal:  Rev Bras Ortop       Date:  2015-11-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.